Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Singular Genomics Systems, Inc.
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Jun-05-23 | Mar-31-23 | Mar-05-23 | Dec-31-22 | Dec-05-22 | Sep-30-22 | Jun-30-22 |
| | 10-Q | 8-K | 10-Q | 8-K | 10-K | 8-K | 10-Q | 10-Q |
| Revenues | 0.5 | 0.5 | 0.9 | 0.9 | 0.8 | 0.8 | 0.0 | 0.0 |
| Cost of goods sold | 0.6 | 0.6 | 0.8 | 0.8 | 0.8 | 0.8 | 0.0 | 0.0 |
| Gross profit | -0.1 | -0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | -18.2% | -18.2% | 10.3% | 6.5% | 1.4% | -3.1% | | |
| Selling, general and administrative [+] | 14.9 | 14.9 | 13.2 | 13.2 | 11.7 | 11.7 | 12.0 | 12.2 |
| General and administrative | | | | | 11.7 | | | |
| Research and development | 12.6 | 12.6 | 12.2 | 12.2 | 10.8 | 10.8 | 12.7 | 12.1 |
| Other operating expenses | | | 0.0 | | 0.0 | | | |
| EBITDA [+] | | | | | -20.1 | | | |
| EBITDA growth | 13.9% | 13.9% | 15.2% | 15.2% | 8.4% | 14.5% | 41.4% | 74.6% |
| EBITDA margin | -5465.9% | -5465.9% | -2819.8% | -2940.7% | -2512.4% | -2945.1% | | |
| Depreciation and amortization | | | | | 2.4 | | | |
| EBIT [+] | -27.6 | -27.6 | -25.4 | -25.4 | -22.5 | -22.5 | -24.7 | -24.2 |
| EBIT growth | 13.9% | 13.9% | 15.2% | 15.2% | 14.5% | 14.5% | 41.4% | 74.6% |
| EBIT margin | -5465.9% | -5465.9% | -2819.8% | -2940.7% | -2816.3% | -2945.1% | | |
| Interest expense | 0.3 | 0.3 | 0.3 | | 0.2 | 0.2 | 0.2 | 0.2 |
| Interest expense | 0.3 | 0.3 | 0.3 | | 0.2 | 0.2 | 0.2 | 0.2 |
| Other income (expense), net [+] | 2.3 | 27.9 | 2.0 | 1.7 | 183.4 | 1.7 | 1.1 | 0.4 |
| Other | | | 1.7 | | | -1.4 | | |
| Pre-tax income | -25.6 | 0.0 | -23.6 | -23.6 | 160.7 | -21.1 | -23.8 | -24.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -25.6 | 0.0 | -23.6 | -23.6 | 160.7 | -21.1 | -23.8 | -24.0 |
| Net margin | -5065.0% | 0.0% | -2625.9% | -2738.5% | 20082.1% | -2758.3% | | |
| |
| Basic EPS [+] | ($0.35) | $0.00 | ($0.33) | ($0.33) | $2.26 | ($0.29) | ($0.33) | ($0.34) |
| Growth | 4.1% | | 6.0% | 6.0% | -40.3% | 7.7% | 36.0% | -71.4% |
| Diluted EPS [+] | ($0.35) | $0.00 | ($0.33) | ($0.33) | $2.26 | ($0.29) | ($0.33) | ($0.34) |
| Growth | 4.1% | | 6.0% | 6.0% | -40.3% | 7.7% | 36.0% | -71.4% |
| |
| Shares outstanding (basic) [+] | 72.5 | 72.5 | 71.9 | 71.9 | 71.1 | 71.6 | 71.2 | 70.8 |
| Growth | 2.4% | 2.4% | 1.3% | 1.3% | 51.3% | -0.8% | -0.7% | 123.8% |
| Shares outstanding (diluted) [+] | 72.5 | 72.5 | 71.9 | 71.9 | 71.1 | 71.6 | 71.2 | 70.8 |
| Growth | 2.4% | 2.4% | 1.3% | 1.3% | 51.3% | -0.8% | -0.7% | 123.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|